Back to Search
STEVEN O'DAY, MD
MD
Surgery Physician
NPI: 1487881017IndividualAccepts Medicare
Specialties, Licenses & Credentials
Surgery PhysicianPrimary
Surgery
Code: 208600000X
0053946(CO)
CMS Specialties
PrimaryGENERAL SURGERY
Education
CREIGHTON UNIVERSITY SCHOOL OF MEDICINE
Class of 2009
Research & Publications (20)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
PMID 18000991·Cancer·2007
6-review
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
PMID 11505406·Cancer·2001
3-trial
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
PMID 19233913·Clin Chem·2009
8-other
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
PMID 19536884·Cancer·2009
3-trial
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
PMID 19671877·Clin Cancer Res·2009
3-trial
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
PMID 19349552·J Clin Oncol·2009
3-trial
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
PMID 19643020·BMC Cancer·2009
3-trial
Phase I/II study of ipilimumab for patients with metastatic melanoma.
PMID 19018089·J Clin Oncol·2008
3-trial
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
PMID 17404088·Clin Cancer Res·2007
8-other
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
PMID 16778184·Cancer Res·2006
8-other
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
PMID 16809738·J Clin Oncol·2006
3-trial
Estrogen receptor-alpha methylation predicts melanoma progression.
PMID 16818643·Cancer Res·2006
8-other
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
PMID 16489066·Clin Cancer Res·2006
8-other
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
PMID 16946711·J Invest Dermatol·2006
8-other
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
PMID 16379038·Invest New Drugs·2006
3-trial
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
PMID 16258104·J Clin Oncol·2005
4-observational
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
PMID 16260693·J Clin Oncol·2005
3-trial
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
PMID 16361635·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2440 N 11TH ST
GRAND JUNCTION, CO 81501 - Phone
- (970) 243-0900
Quick Facts
- NPI
- 1487881017
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile